Scientists in Germany say they've made a nasal vaccine that can shut down Covid-19 infection in the nose and throat. In experiments with hamsters, two doses of the weakened but live coronavirus blocked the virus from copying itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness.
The vaccine has several more hurdles to clear before it's ready for use. However, other nasal vaccines are in use or nearing completion in clinical trials. China and India have already rolled out vaccines given through the nasal tissues, but studies on their effectiveness have yet to be published.
A new approach being explored is boosting mucosal immunity by enhancing immune defenses in the upper airways, where the virus enters the body. This method is similar to stationing firefighters underneath a smoke alarm, according to study author Emanuel Wyler.
The vaccine takes a weakened form of the coronavirus and modifies its genetic material to make it harder for cells to translate. The result is a vaccine that previews the entire coronavirus for the immune system, not just its spike proteins.
Early results from animal studies are promising, with two doses of the nasal vaccine showing a stronger immune response than other types of vaccines. However, vaccine experts caution that more tests need to be conducted before the vaccine can be widely used.
One researcher notes that while this approach is promising, it's essential to develop a pan-coronavirus vaccine that induces mucosal immunity and is long-lived. This would provide better protection against new variants of the virus.
Several nasal vaccines for Covid-19 are currently in late-stage testing in humans, including some that use live but weakened viruses. These include a recombinant vaccine produced cheaply in chicken eggs and one developed by Codagenix, which has shown promising results in South America and Africa.
While these advancements hold promise, there is still concern about the effectiveness of nasal vaccines, particularly against respiratory infections like Covid-19. The challenge lies in delivering an effective vaccine through the nasal tissues without causing harm to people with compromised immune systems.
The vaccine has several more hurdles to clear before it's ready for use. However, other nasal vaccines are in use or nearing completion in clinical trials. China and India have already rolled out vaccines given through the nasal tissues, but studies on their effectiveness have yet to be published.
A new approach being explored is boosting mucosal immunity by enhancing immune defenses in the upper airways, where the virus enters the body. This method is similar to stationing firefighters underneath a smoke alarm, according to study author Emanuel Wyler.
The vaccine takes a weakened form of the coronavirus and modifies its genetic material to make it harder for cells to translate. The result is a vaccine that previews the entire coronavirus for the immune system, not just its spike proteins.
Early results from animal studies are promising, with two doses of the nasal vaccine showing a stronger immune response than other types of vaccines. However, vaccine experts caution that more tests need to be conducted before the vaccine can be widely used.
One researcher notes that while this approach is promising, it's essential to develop a pan-coronavirus vaccine that induces mucosal immunity and is long-lived. This would provide better protection against new variants of the virus.
Several nasal vaccines for Covid-19 are currently in late-stage testing in humans, including some that use live but weakened viruses. These include a recombinant vaccine produced cheaply in chicken eggs and one developed by Codagenix, which has shown promising results in South America and Africa.
While these advancements hold promise, there is still concern about the effectiveness of nasal vaccines, particularly against respiratory infections like Covid-19. The challenge lies in delivering an effective vaccine through the nasal tissues without causing harm to people with compromised immune systems.